Immunology Program

免疫学 免疫学计划的目标是促进以癌症免疫生物学为重点的基础和转化科学，并促进有利于内部和跨计划合作的环境。 这些目标是通过招募和留住优秀的基础和转化科学家，并促进与NC癌症医院临床医生的互动来实现的。25名成员的研究分为两大主题，先天免疫和适应性免疫。在每个主题中有多个子主题，先天免疫主题侧重于癌症和炎症，结肠炎有亮点， 结肠直肠癌和肝炎以及肝细胞癌。其他子主题包括树突状细胞生物学，免疫反应和辐射生物学之间的相互作用，和新的模式传感受体。 适应性免疫程序分为三个子主题，包括疫苗开发，移植物抗宿主生物学和迁移蛋白在T和B淋巴细胞，肿瘤细胞和基质之间的相互作用。研究亮点包括：（1）完成首个临床试验结合标准 乳腺癌患者的疫苗治疗;（2）识别第一个识别病毒核酸的线粒体NLR蛋白;（3）用于预防GvHD的IKK抑制剂的临床前开发;（4）识别趋化因子与迁移基质细胞相互作用以促进肺转移的新途径;（5）新的模型和对先天免疫细胞作为胃肠道中致癌作用的关键介质的相互作用的见解;和（6）开发新的人源化小鼠模型以探索人类免疫系统与癌症发展之间的相互作用。该计划通过促进临床前研究进入临床治疗，建立科学家之间的合作，通过务虚会和每月会议产生科学家和临床医生之间的新合作，并为新的翻译和基础研究提供资金支持，为癌症中心增加了价值。 该项目由Jenny Ting博士领导，先天和分子免疫学的领导者，细胞免疫学、体内成像和疫苗开发领域的领导者。2009年，该计划的25名成员获得了总计1620万美元的校外资金（总成本）。

Immunology The goals of the Immunology Program are to promote basic and translational science focusing on cancer immunobiology and to promote an environment conducive to intra and interprogrammatic collaborations. These goals are achieved by the recruitment and retention of outstanding basic and translational scientists, and the promotion of interactions with clinicians in the NC Cancer Hospital. The 25 members' research is organized into two major themes, innate and adaptive immunity. Within each of the themes are multiple subthemes with the innate immune theme focusing on cancer and inflammation with a spot light on colitis and colorectal cancer and hepatitis and hepatocellular carcinoma. Additional subthemes include dendritic cell biology, interactions between immune response and radiation biology, and novel pattern sensing receptors. The adaptive immune program is divided into three subthemes that include vaccine development, graft-versus-host biology and the role of migratory proteins in the interaction between T and B lymphocytes, tumor cells and the stroma. Research highlights include: (1) completion of the first clinical trial combining standard therapy with vaccine treatment for patients with breast cancer; (2) identification of the first mitochondrial NLR protein that recognizes viral nucleic acid; (3) preclinical development of an IKK inhibitor for the prevention of GvHD; (4) identification of novel pathways in which chemokines interact with migrating stromal cells to promote pulmonary metastasis; (5) new models and Insights into the interaction of innate immune cells as critical mediators of carcinogenesis in the Gl tract; and (6) the development of novel humanized mouse models to explore the interaction between the human immune system and the development of cancer. The program addes value to the Cancer Center by promoting preclinical studies into clinical therapies, forging collaborations between scientists, generating new collaborations between scientists and clinicians via retreats and monthly meetings, and providing funding support for novel translational and basic investigations. The program is led by Dr. Jenny Ting, Ph.D., a leader in innate and molecular immunology and Dr. Jonathan Serody, M.D., a leader in cellular immunology, In vivo imaging and vaccine development. In 2009 the program's 25 members had extramural funding totaling $16.2M (total costs).